Journal of Molecular Modeling

, Volume 19, Issue 3, pp 1227–1236 | Cite as

Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis

  • Juan Felipe Franco-Gonzalez
  • Victor L. Cruz
  • Javier Ramos
  • Javier Martínez-Salazar
Original Paper

Abstract

Human epidermal growth factor receptor 2 (ErbB2) is a transmembrane oncoprotein that is over expressed in breast cancer. A successful therapeutic treatment is a monoclonal antibody called trastuzumab which interacts with the ErbB2 extracellular domain (ErbB2-ECD). A better understanding of the detailed structure of the receptor-antibody interaction is indeed of prime interest for the design of more effective anticancer therapies. In order to discuss the flexibility of the complex ErbB2-ECD/trastuzumab, we present, in this study, a multi-nanosecond molecular dynamics simulation (MD) together with an analysis of fluctuations, through a principal component analysis (PCA) of this system. Previous to this step and in order to validate the simulations, we have performed a detailed analysis of the variable antibody domain interactions with the extracellular domain IV of ErbB2. This structure has been statically elucidated by x-ray studies. Indeed, the simulation results are in excellent agreement with the available experimental information during the full trajectory. The PCA shows eigenvector fluctuations resulting in a hinge motion in which domain II and CH domains approach each other. This move is likely stabilized by the formation of H-bonds and salt bridge interactions between residues of the dimerization arm in the domain II and trastuzumab residues located in the CH domain. Finally, we discuss the flexibility of the MD/PCA model in relation with the static x-ray structure. A movement of the antibody toward the dimerization domain of the ErbB2 receptor is reported for the first time. This finding could have important consequences on the biological action of the monoclonal antibody.

Figure

Trastuzumab Fab approaching the ErbB2 dimerization arm

Keywords

Extracellular ErbB2 receptor Herceptin Molecular dynamics Principal component analysis Trastuzumab 

Notes

Acknowledgments

Thanks are due to the, Comision Interministerial de Ciencia y Tecnologia (CICYT) (MAT2009-12364 and MAT2012-36341 projects) for financial support. The authors also acknowledge Secretaria General Adjunta de Informatica- Consejo Superior de Investigaciones Cientificas (SGAI-CSIC) for technical support during the simulations. One of us (J.R) thanks for financial support through the Ramon y Cajal program, contract RYC-2011-09585. Very fruitful conversations with Dr. Rafael Nuñez during the discussion of literature experimental details are gratefully appreciated.

Supplementary material

894_2012_1661_MOESM2_ESM.pdf (221 kb)
The file “MM-PBSA_calculation.pdf” contains details about the binding energy calculation. (PDF 221 kb)
894_2012_1661_MOESM1_ESM.pdf (1.3 mb)
The file “Additional_information.pdf” contains the following information: Fig. S1. Secondary structures along the trajectory of the different domains found in the ErbB2-ECB/trastuzumab-fab complex as calculated by DSSP analysis. Fig. S2.a) Root mean square deviations (RMSD) as a function of simulation time of the ErbB2-ECD receptor backbone atoms in the complex. b) RMSD along the MD simulation for the backbone atoms for each of the individual domains defined in the ErbB2-ECD protein (domain I in black, II in red, III in green and IV in blue). The complex ErbB2-ECD/trastuzumab-fab crystal structure (PDB code: 1N8Z) was used in all cases as reference structure. (PDF 1322 kb)
894_2012_1661_MOESM3_ESM.avi (1.4 mb)
ESM 1 (AVI 1447 kb)
894_2012_1661_MOESM4_ESM.avi (1.3 mb)
ESM 2 (AVI 1369 kb)
894_2012_1661_MOESM5_ESM.avi (963 kb)
ESM 3 (AVI 963 kb)

References

  1. 1.
    Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefGoogle Scholar
  2. 2.
    Wieduwilt M, Moasser M (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65:1566–1584CrossRefGoogle Scholar
  3. 3.
    Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495–505CrossRefGoogle Scholar
  4. 4.
    Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor-a. Cell 110:763–773CrossRefGoogle Scholar
  5. 5.
    Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775–787CrossRefGoogle Scholar
  6. 6.
    Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507–517CrossRefGoogle Scholar
  7. 7.
    Cho HS, Leahy DJ (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297:1330–1333CrossRefGoogle Scholar
  8. 8.
    Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin fab. Nature 421:756–760CrossRefGoogle Scholar
  9. 9.
    Lu C, Mi LZ, Grey MJ, Zhu J, Graef E, Yokoyama S, Springer TA (2010) Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol 30:5432–5443CrossRefGoogle Scholar
  10. 10.
    Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ (2005) The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci USA 102:15024–15029CrossRefGoogle Scholar
  11. 11.
    Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ErbB2 and discovering ErbB3. Nat Rev 9:463–475Google Scholar
  12. 12.
    Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541–552CrossRefGoogle Scholar
  13. 13.
    Hynes NE, Lane HA (2005) ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354CrossRefGoogle Scholar
  14. 14.
    Vicente-Alique E, Núñez-Ramírez R, Vega JF, Hu P, Martínez-Salazar J (2011) Size and conformational features of ErbB2 and ErbB3 receptors: a TEM and DLS comparative study. Eur Biophys J 40:835–842CrossRefGoogle Scholar
  15. 15.
    DiFiore PP, Pierce JH, Segatto O, King CR, Aaronson SA (1987) ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182CrossRefGoogle Scholar
  16. 16.
    Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137CrossRefGoogle Scholar
  17. 17.
    Junttila TT, Akita RW, Parsons K, Fields C, Phillips GDL, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429–440CrossRefGoogle Scholar
  18. 18.
    Shi X, Xu L, Yu J, Fang X (2009) Study of the inhibition effect of herceptin on interaction between heregulin and ErbB receptors HER2/HER3 by single-molecule force spectrsocopy. Exp Cell Res 315:2847–2855CrossRefGoogle Scholar
  19. 19.
    Garnier N, Genest D, Genest M (1996) Correlated motions and propagation of the effect of a local conformational change in the transmembrane helix of the c-ErbB2 encoded protein and in its V659E mutant, studied by molecular dynamics. Biophys Chem 58:225–237CrossRefGoogle Scholar
  20. 20.
    Samma Soumana O, Aller P, Garnier N, Genest M (2005) Transmembrane peptides from tyrosine kinase receptor. Mutation-related behavior in a lipid bilayer investigated by molecular dynamics simulations. J Biomol Struct Dyn 23:91–100CrossRefGoogle Scholar
  21. 21.
    Duneau JP, Genest D, Genest M (1996) Detailed description of an alpha helix->pi bulge transition detected by molecular dynamics simulations of the p185(c-ErbB2) V659G transmembrane domain. J Biomol Struc Dyn 13:753–769CrossRefGoogle Scholar
  22. 22.
    Garnier N, Crouzy S, Genest M (2003) Molecular dynamics simulations of the transmembrane domain of the oncogenic ErbB2 receptor dimer in a DMPC bilayer. J Biomol Struc Dyn 21:179–199CrossRefGoogle Scholar
  23. 23.
    Samma Soumana O, Garnier N, Genest M (2008) Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search. Eur Biophys J 37:851–864CrossRefGoogle Scholar
  24. 24.
    Bocharov EV, Mineev KS, Volynsky PE, Ermolyuk YS, Tkach EN, Sobol AG, Chupin VV, Kirpichnikov MP, Efremov RG, Arseniev AS (2008) Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem 283:6950–6956CrossRefGoogle Scholar
  25. 25.
    Telesco SE, Radhakrishnan R (2008) Atomistic insights into regulatory mechanisms of the HER2 tyrosine Kinase domain: a molecular dynamics study. Biophys J 96:2321–2334CrossRefGoogle Scholar
  26. 26.
    Shih AJ, Telesco SE, Cho SH, Lemmon MA, Radhakrishnan R (2011) Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. Biochem J 436:241–251CrossRefGoogle Scholar
  27. 27.
    Telesco SE, Shih AJ, Jia F, Radhakrishnan R (2011) A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network. Mol Biosyst 7:2066–2080CrossRefGoogle Scholar
  28. 28.
    Wang JN, Feng JN, Yu M, Xu M, Shi M, Zhou T, Yu XD, Shen BF, Guo N (2003) Structural analysis of the epitopes on ErbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies. Mol Immunol 40:963–969CrossRefGoogle Scholar
  29. 29.
    Hu P, Feng J, Zhou T, Wang J, Jing B, Yu M, Hu M, Zhang X, Shen B, Guo N (2005) In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. J Cell Physiol 205:335–343CrossRefGoogle Scholar
  30. 30.
    Fuentes G, Scaltriti M, Baselga J, Verma CS (2011) Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 13:1–9CrossRefGoogle Scholar
  31. 31.
    SYBYL 8.0, Tripos International, 1699 South Hanley Rd., St. Louis, MO, 63144, USAGoogle Scholar
  32. 32.
    Dayhoff MO, Schwartz RM, Orcutt BC (1978) Atlas of protein sequence and structure. National Biomedical Research Foundation, Washington, DCGoogle Scholar
  33. 33.
    Hess B, Kutzner C, van der Spoel D, Lindahl E, GROMACS 4 (2008) Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comp 4:435–447CrossRefGoogle Scholar
  34. 34.
    Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657–1666CrossRefGoogle Scholar
  35. 35.
    Jorgensen WL, Tirado-Rives J (2005) Chemical theory and computation special feature: potential energy functions for atomic-level simulations of water and organic and biomolecular systems. J Proc Natl Acad Sci USA 102:6665–6670CrossRefGoogle Scholar
  36. 36.
    Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105:6474–6487CrossRefGoogle Scholar
  37. 37.
    Berendsen HJC, Postma JPM, van Gunsteren WF, Hermans J (1981) In: Pullman B (ed) Intermolecular forces. Reidel, Dordrecht, The Netherlands, pp 331–342Google Scholar
  38. 38.
    Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092CrossRefGoogle Scholar
  39. 39.
    Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577–8593CrossRefGoogle Scholar
  40. 40.
    Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81:3684–3690CrossRefGoogle Scholar
  41. 41.
    Hess B, Bekker H, Berendsen HJC, Fraaije J, LINCS (1997) A linear constraint solver for molecular simulations. J Comput Chem 18:1463–1472CrossRefGoogle Scholar
  42. 42.
    Humphrey W, Dalke A, Schulten K, VMD (1996) Visual molecular dynamics. J Mol Graphics 14:33–38CrossRefGoogle Scholar
  43. 43.
    Amadei A, Linssen AB, Berendsen HJ (1993) Essential dynamics of proteins. Proteins 17:412–425CrossRefGoogle Scholar
  44. 44.
    Amadei A, Linssen AB, de Groot BL, van Aalten DM, Berendsen HJ (1996) An efficient method for sampling the essential subspace of proteins. J Biomol Struct Dyn 13:615–625CrossRefGoogle Scholar
  45. 45.
    Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22:2577–2637CrossRefGoogle Scholar
  46. 46.
    Lou H, Cukier RI (2006) Molecular dynamics of apo-adenylate kinase. A principal component analysis J. Phys. Chem B 110: 12796–12808Google Scholar
  47. 47.
    Hunenberger PH, Mark AE, Van Gunsteren WF (1995) Fluctuation and cross-correlation analysis of protein motions observed in nanosecond molecular-dynamics simulations. J Mol Biol 252:492–503CrossRefGoogle Scholar
  48. 48.
    Kaiser HF (1960) The application of electronic-computers to factor-analysis. Educ Psychol Meas 20:141–151CrossRefGoogle Scholar
  49. 49.
    Sobolev V, Eyal E, Gerzon S, Potapov V, Babor M, Prilusky J, Edelman M (2005) SPACE: a suite of tools for protein structure prediction and analysis based on complementarity and environment. Nucl Acids Res 33:W39–W43CrossRefGoogle Scholar
  50. 50.
    Troise F, Cafaro V, Giancola C, D’Alessio G, Lorenzo C (2008) Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. FEBS J 275:4967–4979CrossRefGoogle Scholar
  51. 51.
    Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G (2011) High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLOS 6(4):e17887CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Juan Felipe Franco-Gonzalez
    • 1
  • Victor L. Cruz
    • 1
  • Javier Ramos
    • 1
  • Javier Martínez-Salazar
    • 1
  1. 1.BIOPHYM, Macromolecular Physics DepartmentInstituto de Estructura de la Materia, CSICMadridSpain

Personalised recommendations